SKYE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

SKYE ▼ -4.42% at T+5d

SHORT call ✓ call won +4.42% · α vs SPY +4.50% · entry $0.8140 → $0.7780

Next anchor: T+20d due 3d ago

Currently $0.7870 · +3.32% from $0.8140 entry (call sign-flipped)

Entry anchored
May 12, 01:21 PM ET
via Databento tick

T+1d

+0.74%

call -0.74% · α -0.16%

$0.8200

settled 4w ago

T+5d

-4.42%

call +4.42% · α +4.50%

$0.7780

settled 25d ago

T+20d

—

call — · α —

—

due 3d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Skye Bioscience reported Q1 2026 EPS of -$0.32, missing consensus of -$0.29 by 10.3%, with a net loss of $12.5M vs $11.1M a year ago. The company highlighted clinical progress in its CBeyond expansion study for nimacimab but faces a cash runway only through Q4 2026, excluding Phase 2b costs, creating significant funding uncertainty.

Actionable Insight

The EPS miss and accelerating cash burn without a clear funding path for Phase 2b are negative signals. Monitor the May 18 CRC review for Cohort 1 safety data — a positive read could provide a near-term catalyst, but the fundamental cash constraint limits upside until a financing event occurs.

Key Facts

Q1 2026 EPS -$0.32 vs consensus -$0.29 (10.3% miss)
Net loss widened to $12.5M from $11.1M YoY
Cash, equivalents and short-term investments: $17.1M as of March 31, 2026
Cash runway only through Q4 2026, excluding Phase 2b costs
R&D expenses rose to $7.9M from $7.2M YoY
CBeyond Expansion Study Cohort 1 enrollment initiated; CRC review May 18, 2026
Topline data from CBeyond Expansion Study expected Q4 2026
Weighted average shares outstanding: 39.7M (basic and diluted)

Financial Impact

EPS miss of $0.03 per share; net loss increased by $1.4M YoY; cash burn rate ~$4.3M/month

epsnetLosscashRunway

Risk Factors

Cash runway only through Q4 2026, requiring dilutive financing or partnership to fund Phase 2b
EPS miss of 10.3% vs consensus signals operational underperformance
Net loss widening YoY with no near-term revenue prospects
Clinical trial risk: nimacimab may fail to meet safety/efficacy endpoints in expansion study

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

79% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3293281

6 reports for SKYE

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for SKYE — sortable, filterable
	Type				Now
May 15, 2026 28d ago	8-K BEARISH ★ 7/10	$0.7780 $0.8220	▼ −5.66%	▼ −4.04%	$0.7870 (−1.16%)
May 12, 2026 4w ago	Press Release BEARISH ★ 7/10	$0.8140 $0.7780	▲ +4.42%	▲ +4.50%	$0.7870 (+3.32%)
Apr 29, 2026 6w ago	3 NEUTRAL ★ 2/10	$0.8940 $0.8510	▼ −4.81%	▼ −7.92%	$0.7870 (−11.97%)
Apr 16, 2026 8w ago	DEFA14A NEUTRAL ★ 3/10	$0.7500 $0.8990	▲ +19.87%	▲ +18.88%	$0.7870 (+4.93%)
Apr 2, 2026 10w ago	Press Release MIXED ★ 6/10	$0.6980 $0.7200	▲ +3.15%	▼ −0.47%	$0.7870 (+12.75%)
Mar 10, 2026 13w ago	Press Release MIXED ★ 6/10	$0.7210 $0.6730	▼ −6.66%	▼ −4.47%	$0.7870 (+9.15%)

US Market Status

Market Closed — Opens Mon (49h 11m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access